CEO Michael Farrell reported 10% global revenue growth, driven by demand across the sleep health, breathing health, and residential care software portfolios. Device sales, including AirSense 10 and ...

Sleep-apnoea-tackling Resmed is dreaming big but the question is: what can upset the Aussie biotech's growth story?

Brett Fishbin; Analyst; KeyBanc Capital Markets Inc. Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call ... reflecting the continuing demand for our AirSense 10 and AirSense 11 ...

Due to its significant market share and high gross margins in a structurally growing industry, ResMed has posted an average return on invested capital, or ROIC, of 20% over the last decade. We ...

ResMed has a minority stake in Nyxoah who are developing a neurostimulation implant to treat OSA. Although we see little near ...

ResMed reported a revenue increase of 10% year-over-year ... attributed to manufacturing and cost improvements. The AirSense 11 has become the majority of ResMed's global product mix, which ...

On Friday, Oppenheimer analysts maintained a Perform rating on ResMed (NYSE:RMD) following the company's financial results for the second quarter of fiscal year 2025. ResMed reported a revenue ...

It is similar in some ways to other therapy modes, including CPAP and bilevel. There are pros and cons ... Also known as APAP, auto-titrating, or by brand names such as AirSense (used by ResMed), ...